Experts call for licence extension of stroke drug alteplase

Stroke drug alteplase should have its licence extended so that it can be used more than three hours after stroke onset, experts have said.

Research published in the Lancet Neurology has reinforced previous findings that patients can benefit from alteplase, even if they miss the drug's three-hour treatment window.

However, the benefits of late treatment quickly lessen with time. Patients should therefore be treated as early as possible, the researchers said.

In an editorial published alongside the study, Dr Steven Kasner and Dr Steven Levine of the University of Pennsylvania Medical Centre, said the licence for the drug should be extended to reflect the benefits of using it for eligible patients.

‘Many clinicians are already using alteplase,’ they said. ‘However, some will not use it without regulatory approval, and the time has come to overcome this hurdle.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus